Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

NCT06649721 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT06649721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
Lead sponsor
Huashan Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 27, 2024
Completion date
June 30, 2027
Enrollment
120 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

drug-resistant tuberculosis, pulmonary tuberculosis, rifampin-resistant tuberculosis